自我管理的自身免疫注射剂的全球市场（到 2028 年）

Self-Administered Autoimmune Injectables to 2028

出版日期: 2023年01月04日 | 出版商:

Greystone Research Associates | 英文 160 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

由于广泛影响患者健康和福祉的疾病和适应症数量不断增加，治疗性免疫调节给药正成为越来越重要的医疗选择。然而，为了从人类和收入的角度释放这类疗法的全部价值，开发人员必须应对药物储存和给药的固有挑战，并从静脉给药途径过渡到注射给药途径。用于慢性疾病（如自身免疫）的抗体药物通常会重新配製、重新包装、重新贴上註射剂的标籤，并在上市两到三年后重新上市。这是由于越来越大的经济压力和不需要门诊输液的患者希望自行注射的愿望。

本报告分析了全球自我管理的自身免疫注射剂市场，概述了产品、当前市场推出/开发状态、主要市场驱动因素/制约因素、主要参与者概况以及市场规模/市场份额（到 2028 年） )、资本交易和技术/商业联盟的近期趋势、技术、设计和市场发展问题，以及主要市场背景（经济、技术和监管因素）。我们将收集信息并发送给您。

内容

执行摘要
自行进行自身免疫注射
执行摘要
市场动态
竞争格局
医药供应链活动
产品设计和实现因素
易于使用
患者依从性
给药频率
人体工程学/人体工程学
售前和售后设备的演变
自我管理实现装置
设备选择：稳定性和材料问题
预装注射器
自动注射器
Physioject（Becton Dickinson）
感应笔
Enbrel SureClick（安进）
SmartJect（PA 咨询/Centocor）
Pegasys Proclick（基因泰克/罗氏）
专用自动注射器
注射笔
双腔笔
新设备
自行给药/治疗性自身免疫药物
Actemra（托珠单抗）
Benlysta（葛兰素史克/人类基因组科学）
倍他龙
Cosentyx
Extavia
伊路米娅
齐尼雷特
肿瘤坏死因子
安捷维他
贝尼帕利语
Enbrel（依那西普）
哈利马托兹
赫菲亚
辛波尼（戈利木单抗）
强直性脊柱炎
克罗恩病
成人类风湿性关节炎
幼年特发性关节炎
多发性硬化症
银屑病关节炎
溃疡性结肠炎
市场因素
监管因素
临床试验方案和终点
联盟和伙伴关係
公司简介

简介目录

Product Code: SAK955V

“Self-Administered Autoimmune Injectables to 2028” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this growing segment of the drug delivery sector. The report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, drug device designers, and industry strategists with a detailed understanding of the expanding impact of next generation injection devices on pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

Converging Factors Driving Self-administered Autoimmune Care

The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number of diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward patient enablement and self-administration.

What You Will Learn:

What approved drugs indicated for autoimmune conditions are marketed for self-administration, what is the as-supplied packaging, and who markets them?

What are the major factors driving the migration of infusible drugs for treating autoimmunity to formulations that can be packaged and administered subcutaneously?

What is the size of the market for self-administered autoimmune injectable drugs today, who are the market share leaders, and what will the market share be in 2028?

How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?

What are the essential design factors, technologies and market development issues for devices that can deliver injectable autoimmune drugs subcutaneously?